Meng-Chih Lin

发表

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, The New England journal of medicine.

An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study

J. Shih, Yuh-Min Chen, T. Hsia, 2022, JTO Clinical and Research Reports.

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Ying Cheng, Y. Ohe, S. Ramalingam, 2023, Nature Communications.

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Ying Cheng, J. Barrett, S. Ramalingam, 2019, Journal of Clinical Oncology.

Different Survival Benefit of Osimertinib in Different Sequences: A Real‐World Outcome of Osimertinib Treatment in Pretreated T790M-Positive Advanced NSCLC in Taiwan

Chin-Chou Wang, Huang-Chih Chang, Kuo-Tung Huang, 2021 .

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.

Yi-Lin Wu, W. Su, P. Su, 2021, Lung Cancer.

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

J. Shih, C. Chiu, T. Hsia, 2023, Targeted Oncology.

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

M. Ahn, Keunchil Park, T. Mok, 2016, JAMA oncology.

Solitary pulmonary nodules differentiated by dynamic F-18 FDG PET in a region with high prevalence of granulomatous disease.

Pei-Wen Wang, Yu-Erh Huang, Chih-Feng Chen, 2012, Journal of radiation research.